TEVA PHARMACEUTICAL INDUSTRIES LIMITED Other Comprehensive Income (Loss), before Tax
TEVA PHARMACEUTICAL INDUSTRIES LIMITED (TEVA) reported Other Comprehensive Income (Loss), before Tax of $1.30 billion for the 12-month period ending 2017-12-31, per its 10-K filed 2018-02-12.
Discontinued › Income Statement › Unrealized Gains
us-gaap:OtherComprehensiveIncomeLossBeforeTax · last filed 2018-02-12
- TEVA PHARMACEUTICAL INDUSTRIES LIMITED other comprehensive income (loss), before tax for the quarter ending 2017-12-31 was $341.00M.
- TEVA PHARMACEUTICAL INDUSTRIES LIMITED other comprehensive income (loss), before tax for the quarter ending 2017-09-30 was $203.00M, a 63.71% increase year-over-year.
- TEVA PHARMACEUTICAL INDUSTRIES LIMITED other comprehensive income (loss), before tax for the quarter ending 2017-06-30 was $308.00M, a 142.52% increase year-over-year.
- TEVA PHARMACEUTICAL INDUSTRIES LIMITED other comprehensive income (loss), before tax for the quarter ending 2017-03-31 was $451.00M, a 60.50% increase year-over-year.
- TEVA PHARMACEUTICAL INDUSTRIES LIMITED other comprehensive income (loss), before tax for fiscal 2017 was $1.30B.
- TEVA PHARMACEUTICAL INDUSTRIES LIMITED other comprehensive income (loss), before tax for fiscal 2016 was -$1.18B.
- TEVA PHARMACEUTICAL INDUSTRIES LIMITED other comprehensive income (loss), before tax for fiscal 2015 was -$611.00M.
| Period end | Other Comprehensive Income (Loss), before Tax 3 month | Other Comprehensive Income (Loss), before Tax 3 month as first filed | Other Comprehensive Income (Loss), before Tax 6 month | Other Comprehensive Income (Loss), before Tax 6 month as first filed | Other Comprehensive Income (Loss), before Tax 9 month | Other Comprehensive Income (Loss), before Tax 9 month as first filed | Other Comprehensive Income (Loss), before Tax 12 month |
|---|---|---|---|---|---|---|---|
| 2017-12-31 | $341.00M derived: 10-K 12 month − 6-K 9 month · filed 2018-02-12 | $544.00M derived: sum of 2 quarters · filed 2018-02-12 | $852.00M derived: sum of 3 quarters · filed 2018-02-12 | $1.30B 10-K · filed 2018-02-12 | |||
| 2017-09-30 | $203.00M derived: 6-K 9 month − 6-K 6 month · filed 2017-11-02 | $511.00M derived: sum of 2 quarters · filed 2017-11-02 | $962.00M 6-K · filed 2017-11-02 | $499.00M derived: sum of 4 quarters · filed 2018-02-12 | |||
| 2017-06-30 | $308.00M derived: 6-K 6 month − 6-K 3 month · filed 2017-08-03 | $759.00M 6-K · filed 2017-08-03 | $296.00M derived: sum of 3 quarters · filed 2018-02-12 | $420.00M derived: sum of 4 quarters · filed 2018-02-12 | |||
| 2017-03-31 | $451.00M 6-K · filed 2017-05-11 | -$12.00M derived: sum of 2 quarters · filed 2018-02-12 | $112.00M derived: sum of 3 quarters · filed 2018-02-12 | $239.00M derived: sum of 4 quarters · filed 2018-02-12 | |||
| 2016-12-31 | -$463.00M derived: 10-K 12 month − 6-K 9 month · filed 2018-02-12 | -$339.00M derived: sum of 2 quarters · filed 2018-02-12 | -$212.00M derived: sum of 3 quarters · filed 2018-02-12 | -$1.18B 10-K · filed 2018-02-12 | |||
| 2016-09-30 | $124.00M 6-K · filed 2016-11-15 | $251.00M derived: sum of 2 quarters · filed 2016-11-15 | -$714.00M 6-K · filed 2017-11-02 | $532.00M 6-K · filed 2016-11-15 | -$879.00M derived: sum of 4 quarters · filed 2018-02-12 | ||
| 2016-06-30 | $127.00M 6-K · filed 2016-08-04 | -$557.00M 6-K · filed 2017-08-03 | $408.00M 6-K · filed 2016-08-04 | -$1.00B derived: sum of 3 quarters · filed 2018-02-12 | -$745.00M derived: sum of 4 quarters · filed 2018-02-12 | ||
| 2016-03-31 | $281.00M 6-K · filed 2016-05-09 | -$1.13B derived: sum of 2 quarters · filed 2018-02-12 | -$872.00M derived: sum of 3 quarters · filed 2018-02-12 | -$911.00M derived: sum of 4 quarters · filed 2018-02-12 | |||
| 2015-12-31 | -$1.41B derived: 10-K 12 month − 6-K 9 month · filed 2018-02-12 | -$1.15B derived: sum of 2 quarters · filed 2018-02-12 | -$1.19B derived: sum of 3 quarters · filed 2018-02-12 | -$611.00M 10-K · filed 2018-02-12 | |||
| 2015-09-30 | $258.00M 6-K · filed 2016-11-15 | -$258.00M 6-K · filed 2015-10-29 | $219.00M derived: sum of 2 quarters · filed 2016-11-15 | $800.00M 6-K · filed 2016-11-15 | -$800.00M 6-K · filed 2015-10-29 | $290.00M derived: sum of 4 quarters · filed 2017-02-15 | |
| 2015-06-30 | -$39.00M 6-K · filed 2016-08-04 | $39.00M 6-K · filed 2015-07-30 | $542.00M 6-K · filed 2016-08-04 | -$542.00M 6-K · filed 2015-07-30 | $32.00M derived: sum of 3 quarters · filed 2017-02-15 | -$552.00M derived: sum of 4 quarters · filed 2017-02-15 | |
| 2015-03-31 | $581.00M 6-K · filed 2016-05-09 | -$581.00M 6-K · filed 2015-04-30 | $71.00M derived: sum of 2 quarters · filed 2017-02-15 | -$513.00M derived: sum of 3 quarters · filed 2017-02-15 | -$522.00M derived: sum of 4 quarters · filed 2017-02-15 | ||
| 2014-12-31 | -$510.00M derived: 20-F 12 month − 6-K 9 month · filed 2017-02-15 | -$1.09B derived: sum of 2 quarters · filed 2017-02-15 | -$1.10B derived: sum of 3 quarters · filed 2017-02-15 | -$1.26B 20-F · filed 2017-02-15 | |||
| 2014-09-30 | -$584.00M 6-K · filed 2015-10-29 | -$593.00M derived: sum of 2 quarters · filed 2015-10-29 | -$754.00M 6-K · filed 2015-10-29 | -$691.00M derived: sum of 4 quarters · filed 2016-02-11 | |||
| 2014-06-30 | -$9.00M 6-K · filed 2015-07-30 | -$165.00M 6-K · filed 2015-07-30 | -$107.00M derived: sum of 3 quarters · filed 2016-02-11 | $196.00M derived: sum of 4 quarters · filed 2016-02-11 | |||
| 2014-03-31 | -$163.00M 6-K · filed 2015-04-30 | -$98.00M derived: sum of 2 quarters · filed 2016-02-11 | $205.00M derived: sum of 3 quarters · filed 2016-02-11 | -$3.00M derived: sum of 4 quarters · filed 2016-02-11 | |||
| 2013-12-31 | $65.00M derived: 20-F 12 month − 6-K 9 month · filed 2016-02-11 | $368.00M derived: sum of 2 quarters · filed 2016-02-11 | $160.00M derived: sum of 3 quarters · filed 2016-02-11 | -$77.00M 20-F · filed 2016-02-11 | |||
| 2013-09-30 | $303.00M 6-K · filed 2014-10-30 | $95.00M derived: sum of 2 quarters · filed 2014-10-30 | -$142.00M 6-K · filed 2014-10-30 | ||||
| 2013-06-30 | -$208.00M 6-K · filed 2014-07-31 | -$445.00M 6-K · filed 2014-07-31 | |||||
| 2013-03-31 | -$237.00M 6-K · filed 2014-05-02 |